Healthcare Services

The Ares Specialty Healthcare Fund is a specialized direct‑lending vehicle managed by Ares Management, formed to provide flexible capital solutions to companies operating across the specialty healthcare ecosystem. It focuses on industries such as pharmaceuticals, biotechnology, medical technologies and diagnostics, specialist healthcare services and healthcare IT where companies often face constraints accessing traditional bank financing or need transformational capital. The fund is structured to invest across the capital structure — from first‑ and second‑lien senior secured loans, to mezzanine debt, preferred equity and minority equity stakes — enabling the team to tailor solutions to companies undergoing growth or transformation. It targets businesses in North America and Europe and is backed by a dedicated investment team and industry advisory board with deep healthcare operating expertise. Recognising enduring structural trends — an aging population, innovation in diagnostics and medtech, increasing digitalisation of healthcare and shifting service models — the fund seeks to invest in companies with resilient demand and growth potential. It aims to deliver both defensive characteristics (i.e., non‑cyclical healthcare demand) and meaningful upside from innovation and transformation in the healthcare value chain. By partnering with firms across the healthcare spectrum — from device manufacturers and diagnostics players to niche specialty services and healthcare IT platforms — the fund aims to fill a financing gap and support businesses that are scaling, executing roll‑ups or transforming their offerings. The strategy leverages Ares’ broader credit platform and healthcare expertise to structure creative, non‑dilutive capital solutions in an increasingly competitive healthcare financing environment.

Compass Group Fund III has closed at a hard cap of $408 million, representing the firm’s second fundraising effort in the past two years. The fund focuses on thematic research and investment in the lower middle market, specifically targeting subsectors within niche manufacturing & distribution and business & consumer services industries. The geographical focus of the fund is the Mid-America “Between the Mountain Ranges,” with a strategic emphasis on the Midwestern region. The fund seeks to invest in historically successful entrepreneur and family-owned companies that exhibit characteristics such as EBITDA between $2 million and $15 million, enterprise values of $20 million to $200 million, and strong margin and cash flow generation. Compass Group aims to provide long-term capital and strategic support to small-to-medium sized private companies with revenues between $20-$100 million, typically investing $10-$30 million in control positions. The firm prioritizes partnering with businesses that have reached an inflection point for growth and are seeking continued participation and partnership, especially those without prior institutional capital. Additionally, Compass Group looks for niche markets with $100M+ potential that are highly fragmented with no clear leader or category disruption, further demonstrating the fund’s strategic focus on specific sectors and types of businesses.

The Comvest Investment Partners VI, L.P. fund (CIP VI) is a private equity that has closed with total capital commitments of $881 million. The fund targets control investments in market-leading middle-market companies throughout North America, with a focus on industries such as consumer, healthcare services, infrastructure and field services, and professional and managed services. The fund seeks to deploy up to $150 million of equity per investment and supports founder and family transitions, leveraged recapitalizations, corporate divestitures, buyouts, complex situations, and public-to-private transactions. The fund received commitments from a diverse global investor group that includes foundations, insurance companies, pension funds, asset managers, consultants, and family offices. Comvest Partners, the firm managing the fund, has nearly 25 years of experience in delivering results for investors and a proven investment team. Comvest's private equity strategy integrates specialized investment, industry, and operational expertise to help company founders and management teams scale their businesses, heighten operational performance, and drive value creation to realize their full potential. The firm has a collaborative approach and significant transaction experience as an active investor.

Equitage Ventures Fund I is a $47.3 million early-stage venture capital fund launched in April 2025 by Denver-based Equitage Ventures. The fund focuses on investing in technology and technology-enabled services that address the physical, mental, spiritual, and social needs of older adults. Led by a team of seasoned investors and operators—Russell Hirsch (co-founder of Generator Ventures), Adam Kaplan (CEO of Solera Senior Living), and Daniel Kaplan (AgeTech investor)—the fund aims to reshape how senior care is delivered through innovation and scale. Equitage partners with senior living and skilled nursing operators, home health and hospice agencies, healthcare tech firms, and consumer brands. These limited partners not only provide capital, but also strategic input, distribution channels, and hands-on support to accelerate portfolio growth. The fund focuses on critical areas of need and opportunity, including compliance infrastructure, documentation automation, passive monitoring, dementia and behavioral health, oral health, care navigation, and family caregiving support. Equitage takes a founder-friendly, collaborative approach, often investing between $250,000 and $2.5 million per company, and positioning itself as a long-term partner offering more than just capital. The fund seeks to create meaningful change in senior care by supporting scalable, impactful innovations across the U.S.

Escalate Capital V is a growth capital fund by Escalate Capital Partners. The fund is located in Austin, Texas and prefers investing in United Sates. The fund targets technology, software, services, and healthcare sectors. The fund invests in rapidly growing later-stage companies with minimum revenues of $20 million and minimum EBITDA of $3 million. Sectors of interest include technology, software, services, and healthcare across the United States. As of May 2025, the fund has already closed on two investments representing $35 million of Fund V’s committed capital. Since its founding in 2005, Escalate has invested over $1.3 billion of capital in 140 growth equity-backed companies.

The fund is the fourth flagship vehicle from GHO Capital, leveraging its deep specialization in healthcare to back companies delivering better, faster and more accessible care. With its final close at over €2.5 billion, the vehicle is positioned to scale high‑growth businesses across services, medtech, diagnostics and health‑tech platforms. GHO Capital IV focuses on companies where strong management, operational improvement and international expansion can unlock significant value. The fund partners with leadership teams in niche but growing healthcare subsectors and applies the firm’s sector insight, global network and operational resources to drive transformation. The strategy targets enterprises that serve pharmaceutical, biotechnology and medical device customers — such as CDMOs, contract services, outsourcing platforms, diagnostics manufacturers and digital health enablers — where structural tailwinds and under‑penetrated markets offer runway for growth. Geographically, the fund emphasises Europe and North America but retains flexibility to leverage cross‑border dynamics, enabling portfolio companies to scale internationally. Through disciplined buy‑outs, add‑on consolidation and operational acceleration, GHO Capital IV aims to d

The $750 million private equity multi-asset continuation fund announced by Hildred Capital is focused on healthcare and specializes in partnering with middle-market companies. The fund was structured to align the interests of the general partnership and limited partners, with the co-founders rolling over 100% of their economic interests into the continuation fund. Limited partners had the option to roll all, sell all, or sell a portion of their interests and roll a portion into the continuation fund. This fund aims to provide additional committed capital for companies to execute organic growth initiatives, pursue strategic acquisitions, and continue to drive operating leverage. It has generated significant liquidity and attractive returns for selling limited partners while also providing new investors with the opportunity to participate over time in the appreciation of strong and growing companies.

LAV Fund VII is a $547 million venture capital fund managed by Lilly Asia Ventures (LAV), a biomedical investment firm with offices in Shanghai, Hong Kong, and Palo Alto. The fund reached its hard cap in April 2025 and is structured as a Cayman Islands limited partnership. LAV Fund VII continues LAV's mission to support companies developing breakthrough products that treat diseases and improve human health. The fund targets early- to growth-stage investments in biopharmaceuticals, human therapeutics, medical devices, and diagnostics. The fund's limited partners include the San Francisco Employees' Retirement System, which committed $50 million.

Linden Capital Partners, a Chicago-based private equity firm specializing in healthcare, has successfully closed its sixth buyout fund, Linden Capital Partners VI, at $5.4 billion. This marks a major milestone, surpassing its $4.5 billion target and initial $5.0 billion hard cap. The fund secured $5.2 billion in LP commitments from investors in more than 20 countries, along with a $200 million general partner commitment. Fund VI will continue Linden’s long-standing strategy of investing in middle-market healthcare companies, with a focus on services, products, and distribution segments. The firm brings a disciplined approach to value creation, combining deep operational expertise, tailored growth strategies, and a unique human capital model to support long-term success. The fund's investor base includes major institutional investors such as the New York State Teachers’ Retirement System, Texas County & District Retirement System, Louisiana State Employees’ Retirement System, Sacramento County Employees’ Retirement System, and Fairfax County Educational Employees’ Supplementary Retirement System. The oversubscribed fund closed in under nine months, highlighting strong investor demand and Linden’s leadership in healthcare investing.

NewSpring Health Capital IV is a growth equity fund that targets high-growth, lower-middle market companies focused on technology-enabled healthcare services and niche clinical providers. The fund aims to invest in companies that influence healthcare by using technology and human capital in novel ways, with a focus on easing access to care, improving outcomes, and increasing efficiency while lowering costs. With a focus on proprietary deal flow, the fund has made investments in specialized pharmaceutical distribution services, sleep disorders management, cardiovascular staffing, dysphagia diagnostics, business process outsourcing services for behavioral health programs, and healthcare disclosure management technology and services. The fund's target investments are companies that evolve and shape high-impact sectors in healthcare. NewSpring Health Capital IV seeks to invest from $10 to $25 million in lower-middle market companies that have between $10 to $100 million in revenue at the time of investment. The fund has raised over $180 million and received strong support from existing and new investors, including a diverse group of strategics, financial institutions, and family offices. The fund is led by a team with extensive expertise in different segments of healthcare, including a team of advisory partners with deep industry experience. With a deep and growing deal pipeline of innovative healthcare companies, the fund will capitalize on the escalating opportunities and growing momentum within this segment of the market.

Quadria Capital Fund III is a growth-stage private equity vehicle focused on transforming healthcare systems across South and Southeast Asia. With $1.07 billion in commitments, the fund aims to build a diversified portfolio of approximately 10 market-leading companies, taking both significant minority and majority stakes. The fund has already deployed nearly 40% of its capital, including investments in Aragen Life Sciences, NephroPlus, and Maxivision Eye Hospital.The fund targets sectors such as healthcare delivery, life sciences, medical technology, and associated healthcare services. It seeks to invest in companies that provide high-quality, affordable healthcare solutions, leveraging technology and innovation to address the growing demand in the region. Quadria Capital's strategy includes partnering with exceptional healthcare businesses to enhance their impact and scale, while generating superior returns for investors.Quadria Capital Fund III has attracted a diverse group of investors, including sovereign wealth funds, asset managers, strategic corporates, and impact investors from North America, Europe, the Gulf Cooperation Council, and Asia. The fund's focus on healthcare transformation aligns with the increasing need for accessible and affordable healthcare services in rapidly growing markets.

Vivo Opportunity Fund III is the latest iteration of Vivo Capital's evergreen equity fund, structured in three-year investment cycles. With over $740 million in commitments, the fund continues its focus on small- and mid-cap biotechnology and life sciences companies, particularly those developing or commercializing novel therapies targeting unmet medical needs. The fund primarily backs preclinical and clinical-stage companies, aiming to realize value through scientific breakthroughs and pivotal clinical milestones. Vivo Capital employs a hybrid strategy that combines public market investing with a venture capital approach, leveraging the firm’s technical expertise to identify high-potential healthcare assets. Vivo has a strong track record, with previous Opportunity Funds supporting companies that have reached major inflection points, such as FDA approvals or strategic acquisitions. Noteworthy examples include investments in Verona Pharmaceuticals, Geron Corporation, and Soleno Therapeutics.